July 31, 2018
Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer
Progression free survival of patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the results of its INNOVATE phase 2 pilot trial have been published in… Read More
learn more
July 26, 2018
Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update
Quarterly net revenues of $61.5 million, representing 60 percent growth versus the second quarter 2017 and 18 percent growth versus the first quarter 2018 Submission of local coverage determination reconsideration request to the durable medical equipment Medicare administrative contractors following June CMS announcement of new payment rules for… Read More
learn more
July 19, 2018
Novocure Announces 13 Presentations at American Society for Radiation Oncology 2018 Annual Meeting
The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference Highlights include an analysis of the RTOG RPA scores in Novocure’s EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma and the first presentation of an analysis of the correlation… Read More
learn more
July 17, 2018
Scientific Track Dedicated to Tumor Treating Fields at 40th International Conference of the IEEE Engineering in Medicine and Biology Society
The IEEE Engineering in Medicine and Biology Society’s 40th International Conference is the first conference in which a scientific track will be devoted to Tumor Treating Fields, increasing the awareness of Novocure’s proprietary cancer therapy among the scientific community The conference will feature seven oral presentations on Tumor… Read More
learn more
July 2, 2018
Novocure Appoints Pritesh Shah as Chief Commercial Officer
With extensive experience in oncology, Pritesh Shah will be responsible for Novocure’s commercial strategy worldwide ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that Pritesh Shah has been appointed as Novocure’s Chief Commercial Officer, reporting to Novocure’s Chief Executive Officer Asaf Danziger. In this role, Mr. Shah will… Read More
learn more
July 2, 2018
Novocure to Report Second Quarter 2018 Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2018 on Thursday, July 26, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and… Read More
learn more
